Please assess the completion status of the following clinical trial:

Trial Title: Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:.~1. Ages 4 to 18 years old,~2. Non-infectious uveitis~3. Persistent uveitis uncontrolled by topical medications, or unacceptable side effects of topical medications.~4. Failure of at least six weeks of treatment with a non-biological disease modifying agent such as methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine.~5. Ability to provide informed consent (subject or parent/guardian)~6. Onset of uveitis \< 16 years of age.~7. Topical ophthalmologic treatments allowed.~8. Systemic corticosteroid use at entry may be allowed.~9. Willingness to use acceptable contraception if sexually active for the duration of the study and for 6 months after receiving the last infliximab infusion.~10. Concomitant methotrexate must be taken at time of initiation of infliximab~11. Participant must be able to cooperate for a non-sedated slit lamp exam and visual acuity examination.~12. Negative Purified Protein Derivative (PPD) placed and read within 1 month of initiation of infliximab~13. The screening laboratory test results must meet the following criteria:~    * WBC (white blood cell count): within normal range for institution~   * ANC (absolute neutrophil count): within normal range for institution~   * Hemoglobin: greater than 10 grams/deciliter~   * Platelets: within normal range for institution~   * Serum Creatinine: within normal range for age~   * AST - aspartate aminotransferase - within normal range for institution~   * ALT - alanine aminotransferase- within normal range for institution~Exclusion Criteria:~1. Previous use of biologic medications for uveitis.~2. Intraocular steroid injection or ophthalmologic surgery within the preceding 3 months.~3. Uveitis due to trauma or intraocular surgery~4. Females who are pregnant, nursing, or planning pregnancy within 6 months after the last infliximab infusion.~5. Males who plan on fathering a child within 6 months after their last infliximab infusion.~6. A history of a known allergy to murine products.~7. Documentation of seropositivity for human immunodeficiency virus (HIV).~8. Documentation of a positive test for hepatitis B surface antigen or hepatitis C~9. A known history of a serious infection (e.g., hepatitis, pneumonia, or pyelonephritis) in the previous 3 months.~10. An opportunistic infection (e.g., herpes zoster \[shingles\], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening.~11. A concomitant diagnosis or history of congestive heart failure.~12. A history of lymphoproliferative disease.~13. Any known malignancy or a history of malignancy.~14. Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.~15. Use of any investigational drug within 30 days prior to screening or within five half-lives of the first dose of the investigational agent, whichever is longer.~16. Presence of a transplanted solid organ.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 5mg/kg/dose of infliximab IV every 4 weeks for 9 doses
- 2 (Type: ACTIVE_COMPARATOR): 10mg/kg/dose of infliximab IV every 4 weeks for 9 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).